Search Bar & Filters
Found 6 Actively Recruiting clinical trials
Actively Recruiting
Researchers are investigating new treatments for neovascular age-related macular degeneration NVAMD, a condition that affects the eye and vision. This trial aims to compare a new medicine called tiespectus also known as MK-8748 or EYE201 with the standard treatment aflibercept to see if tiespectus works as well for people with NVAMD. The study is a randomized, double-masked, pivotal phase 23 trial focusing on treatment effectiveness and safety. Participants will be assigned to one of three groups one receiving a low dose of tiespectus, another receiving a high dose of tiespectus, and a third group receiving aflibercept. In the tiespectus groups, participants will get three initial injections every four weeks, followed by injections every eight weeks until week 48. After week 48, treatment intervals will be personalized based on individual responses, continuing up to week 92. The aflibercept group also receives three initial injections followed by injections every eight weeks until week 92. Throughout the study, participants will have their vision assessed using a standard eye chart to measure changes in best-corrected visual acuity BCVA from the start through one year. Additional measures include eye imaging to assess retinal thickness and monitoring for any side effects or adverse events up to approximately 96 weeks. The trial will last until June 2028, with ongoing monitoring and follow-up visits to evaluate the safety and effectiveness of the treatments.
Actively Recruiting
Researchers are investigating new treatments for diabetic macular edema DME, a condition that can cause vision loss. This trial aims to compare the effects of a new medicine called MK-8748 with the current standard treatment, aflibercept, to see if MK-8748 works as well. The study focuses on adults with type 1 or type 2 diabetes who have vision decrease due to DME. Participants will be randomly assigned to one of three groups two groups receive different doses of MK-8748 via injections into the eye, starting with five doses every 4 weeks, then every 8 weeks until week 48, followed by treatment intervals based on individual response up to week 100. The third group receives aflibercept injections on a similar schedule for up to 100 weeks. The study is double-masked and multicenter, designed to carefully compare these treatments. During the trial, participants will have regular eye examinations, including measurements of visual acuity and retinal thickness, along with imaging tests such as optical coherence tomography and fluorescein angiography. Researchers will monitor changes in vision and eye condition over one to two years, assess treatment safety, and track adverse events and drug levels. The main outcome measured is the change in best-corrected visual acuity after one year of treatment.
Actively Recruiting
Researchers are evaluating the safety and preliminary effects of THN391, an investigational drug given as an eye injection, in adults with diabetic macular edema DME caused by non-proliferative diabetic retinopathy. This phase 1b study aims to understand how well THN391 is tolerated and its biological activity in this eye condition. Approximately 21 participants will be enrolled in three groups receiving increasing doses of the drug. Participants will receive three monthly intravitreal injections of THN391 at low, medium, or high doses depending on their assigned group. The study is open-label, meaning everyone knows the dose being given. The treatment period includes these three monthly doses and monitoring for up to 16 weeks after the first dose to assess safety and changes in vision and retinal swelling. During the study, participants will have regular assessments of their eye health including vision tests and retinal examinations. Researchers will track adverse events and measure changes in visual acuity and retinal edema. The total follow-up period lasts up to 16 weeks after the initial dose. The study does not include a placebo group and is designed to carefully monitor safety and biological responses to the drug.
Actively Recruiting
Researchers are studying geographic atrophy GA secondary to age-related macular degeneration AMD to understand how different doses of the drug FWY003 affect the condition. This randomized, double-masked, multi-center study aims to characterize the dose-response relationship, as well as assess the efficacy and safety of FWY003 compared to a placebo in adults aged 50 and older with GA due to AMD. Participants are randomly assigned to receive one of three dose levels of FWY003 or a placebo. The study drug or placebo is administered as part of a controlled treatment plan over an 18-month period. The trial includes multiple study groups to compare effects across doses and between the active drug and placebo. During the study, participants will undergo regular assessments including measurements of GA lesion size, visual function tests such as best corrected visual acuity under regular and low luminance, contrast sensitivity, and plasma drug levels. Safety is monitored through adverse event tracking from the first dose through month 19. The main outcome is the change in GA lesion area from baseline to month 18, with treatment effects and safety followed over this period.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating ways to improve hepatitis C virus HCV care in drug treatment clinics and needle and syringe programs in New South Wales and across Australia. The ETHOS II Project aims to develop a framework to establish HCV screening and treatment programs in these settings nationally. This collaborative research involves several health organizations and focuses on people with a history of injecting drug use or those receiving opioid substitution therapy. The study includes an intervention called campaign days where participants receive hepatitis C screening, liver fibrosis assessments using fibroscans, and clinical assessments. Participants also complete surveys and may consent to link their data with population databases. A sub-study involves collecting blood samples from some participants to evaluate new diagnostic tests for chronic HCV infection. Additionally, interviews with policymakers, clinicians, and patients will explore barriers to HCV care, and an education program will be developed to improve workforce knowledge and care quality. Participants will be recruited from drug treatment clinics, general practitioners with high case loads, and needle and syringe programs. They will undergo hepatitis C testing, fibroscans, clinical assessments, and complete questionnaires during the campaign days. Researchers will track how many participants start anti-HCV treatment each year for up to three years. The study also includes follow-up through medical record reviews to monitor outcomes and improve treatment access and delivery.
Actively Recruiting
Researchers are evaluating the drug ADX-038 in participants aged 60 years and older who have geographic atrophy GA secondary to age-related macular degeneration AMD. This Phase 2, randomized, masked, placebo-controlled study aims to compare the effects of ADX-038 with a placebo on preserving the ellipsoid zone EZ layer in the eye over 12 months. The trial will also assess the safety, pharmacokinetics, and pharmacodynamics of ADX-038. Participants will receive either subcutaneous injections of ADX-038, a siRNA duplex oligonucleotide, or a saline placebo. The study uses a parallel design where participants are randomly assigned to one of these two groups. The treatment is administered over a 12-month period, during which the impact on eye structure and function will be closely monitored. Throughout the study, participants will attend clinic visits for assessments, including high-quality fundus imaging and other study-related procedures. They must complete meningococcal and pneumococcal vaccinations as required by the protocol. Researchers will monitor the preservation of the EZ layer as the primary outcome to evaluate treatment effect, alongside safety and drug behavior in the body. The total study duration extends until August 2030, with primary outcome results expected by February 2030.